Tower Research Capital LLC TRC Purchases 6,823 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Tower Research Capital LLC TRC increased its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 52.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,867 shares of the biopharmaceutical company’s stock after buying an additional 6,823 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Emergent BioSolutions were worth $48,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Jacobs Levy Equity Management Inc. raised its stake in shares of Emergent BioSolutions by 0.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,246,020 shares of the biopharmaceutical company’s stock valued at $4,236,000 after purchasing an additional 11,573 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Emergent BioSolutions by 356.2% in the 4th quarter. Assenagon Asset Management S.A. now owns 834,372 shares of the biopharmaceutical company’s stock worth $2,002,000 after buying an additional 651,480 shares during the period. Hsbc Holdings PLC lifted its stake in shares of Emergent BioSolutions by 295.4% in the 3rd quarter. Hsbc Holdings PLC now owns 75,133 shares of the biopharmaceutical company’s stock valued at $250,000 after purchasing an additional 56,129 shares during the period. CoreCap Advisors LLC purchased a new position in shares of Emergent BioSolutions in the 4th quarter valued at approximately $33,000. Finally, SG Americas Securities LLC increased its position in Emergent BioSolutions by 171.7% during the 4th quarter. SG Americas Securities LLC now owns 66,011 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 41,712 shares in the last quarter. Institutional investors own 78.40% of the company’s stock.

Analysts Set New Price Targets

Separately, Benchmark reissued a “buy” rating and issued a $5.00 target price on shares of Emergent BioSolutions in a report on Thursday, April 11th.

Emergent BioSolutions Trading Down 0.5 %

EBS stock traded down $0.01 during midday trading on Tuesday, reaching $1.88. 987,669 shares of the company traded hands, compared to its average volume of 2,570,018. Emergent BioSolutions Inc. has a 52-week low of $1.42 and a 52-week high of $10.88. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.54 and a current ratio of 1.04. The business has a 50 day moving average of $2.46 and a 200-day moving average of $2.22. The firm has a market capitalization of $98.49 million, a price-to-earnings ratio of -0.13 and a beta of 1.20.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings data on Wednesday, March 6th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.44). The firm had revenue of $276.60 million during the quarter, compared to the consensus estimate of $247.63 million. Emergent BioSolutions had a negative return on equity of 37.35% and a negative net margin of 72.11%. During the same period last year, the company earned ($0.31) EPS. As a group, sell-side analysts expect that Emergent BioSolutions Inc. will post -13.98 earnings per share for the current fiscal year.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.